Zensun eyes US Phase III start for first-in-class CHF drug
This article was originally published in Scrip
Executive Summary
Ahead of initiating a US Phase III program for Neucardin, a novel biologic therapy for chronic heart failure (CHF), Zensun (Shanghai) Science & Technology has provided a brief glimpse at positive interim Phase II data generated in this territory.